SumayaVac-1 (SUM-101) is a novel recombinant, full-length merozoite surface protein 1 (MSP1)-based malaria vaccine candidate developed by Sumaya Biotech to target both the asymptomatic liver stages and disease-causing blood stages of Plasmodium falciparum
SumayaVac-1 (SUM-101) is a novel recombinant, full-length merozoite surface protein 1 (MSP1)-based malaria vaccine candidate developed by Sumaya Biotech to target both the asymptomatic liver stages and disease-causing blood stages of Plasmodium falciparum
